Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Stroke | Original investigation

Chronic kidney disease and undiagnosed atrial fibrillation in individuals with diabetes

Authors: Nam Ju Heo, Sang Youl Rhee, Jill Waalen, Steven Steinhubl

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Diabetes is an independent risk factor for atrial fibrillation (AF), which is associated with increases in mortality and morbidity, as well as a diminished quality of life. Renal involvement in diabetes is common, and since chronic kidney disease (CKD) shares several of the same putative mechanisms as AF, it may contribute to its increased risk in individuals with diabetes. The objective of this study is to identify the relationship between CKD and the rates of newly-diagnosed AF in individuals with diabetes taking part in a screening program using a self-applied wearable electrocardiogram (ECG) patch.

Materials and methods

The study included 608 individuals with a diagnosis of diabetes among 1738 total actively monitored participants in the prospective mHealth Screening to Prevent Strokes (mSToPS) trial. Participants, without a prior diagnosis of AF, wore an ECG patch for 2 weeks, twice, over a 4-months period and followed clinically through claims data for 1 year. Definitions of CKD included ICD-9 or ICD-10 chronic renal failure diagnostic codes, and the Health Profile Database algorithm. Individuals requiring dialysis were excluded from trial enrollment.

Results

Ninety-six (15.8%) of study participants with diabetes also had a diagnosis of CKD. Over 12 months of follow-up, 19 new cases of AF were detected among the 608 participants. AF was newly diagnosed in 7.3% of participants with CKD and 2.3% in those without (P < 0.05) over 12 months of follow-up. In a univariate Cox proportional hazard regression analysis, the risk of incident AF was 3 times higher in individuals with CKD relative to those without CKD: hazard ratios (HR) 3.106 (95% CI 1.2–7.9). After adjusting for the effect of age, sex, and hypertension, the risk of incident AF was still significantly higher in those with CKD: HR 2.886 (95% CI 1.1–7.5).

Conclusion

Among individuals with diabetes, CKD significantly increases the risk of incident AF. Identification of AF prior to clinical symptoms through active ECG screening could help to improve the clinical outcomes in individuals with CKD and diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–24.CrossRef Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–24.CrossRef
2.
go back to reference Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4.CrossRef Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4.CrossRef
3.
go back to reference Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D’Agostino RB. Newly diagnosed atrial fibrillation and acute stroke: the Framingham Study. Stroke. 1995;26(9):1527–30.CrossRef Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D’Agostino RB. Newly diagnosed atrial fibrillation and acute stroke: the Framingham Study. Stroke. 1995;26(9):1527–30.CrossRef
4.
go back to reference Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke. Stroke. 2011;42(2):517–84.CrossRef Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke. Stroke. 2011;42(2):517–84.CrossRef
5.
go back to reference Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRef Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRef
6.
go back to reference Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRef Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRef
7.
go back to reference Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske B, Kutner N, et al. US renal data system 2012 annual data report. Am J Kidney Dis. 2013; 61(1 Suppl 1): A7, e1-476. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske B, Kutner N, et al. US renal data system 2012 annual data report. Am J Kidney Dis. 2013; 61(1 Suppl 1): A7, e1-476.
8.
go back to reference Verde E, Pérez de Prado A, López-Gómez JM, Quiroga B, Goicoechea M, García-Prieto A, Torres E, Reque J, Luño J. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol. 2016;11:2210–7.CrossRef Verde E, Pérez de Prado A, López-Gómez JM, Quiroga B, Goicoechea M, García-Prieto A, Torres E, Reque J, Luño J. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol. 2016;11:2210–7.CrossRef
9.
go back to reference Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20(12):1929–35.CrossRef Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20(12):1929–35.CrossRef
10.
go back to reference Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382(1):20–8.CrossRef Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382(1):20–8.CrossRef
11.
go back to reference Roberts PR, Zachariah D, Morgan JM, Yue AM, Greenwood EF, Phillips PC, Kalra PA, Green D, Lewis RJ, Kalra PR. Monitoring of arrhythmia and sudden death in a hemodialysis population: the CRASH-ILR Study. PLoS ONE. 2017;12:e0188713.CrossRef Roberts PR, Zachariah D, Morgan JM, Yue AM, Greenwood EF, Phillips PC, Kalra PA, Green D, Lewis RJ, Kalra PR. Monitoring of arrhythmia and sudden death in a hemodialysis population: the CRASH-ILR Study. PLoS ONE. 2017;12:e0188713.CrossRef
12.
go back to reference Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM, Di M. MiD Investigators and Committees: primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93:941–51.CrossRef Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM, Di M. MiD Investigators and Committees: primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93:941–51.CrossRef
13.
go back to reference Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, Katz R, Kestenbaum B, Mathew J, Robinson-Cohen C, et al. eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12:1386–98.CrossRef Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, Katz R, Kestenbaum B, Mathew J, Robinson-Cohen C, et al. eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12:1386–98.CrossRef
14.
go back to reference Akoum N, Zelnick LR, de Boer IH, Hirsch IB, Trence D, Henry C, Robinson N, Bansal N. Rates of cardiac rhythm abnormalities in patients with CKD and diabetes. Clin J Am Soc Nephrol. 2019;14:549–56.CrossRef Akoum N, Zelnick LR, de Boer IH, Hirsch IB, Trence D, Henry C, Robinson N, Bansal N. Rates of cardiac rhythm abnormalities in patients with CKD and diabetes. Clin J Am Soc Nephrol. 2019;14:549–56.CrossRef
15.
go back to reference Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis. 2015;108(4):269–76.CrossRef Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis. 2015;108(4):269–76.CrossRef
16.
go back to reference Kim YG, Han K, Choi J, Boo KY, Kim DY, Oh SK, Lee KN, Shim J, Kim JS, Kim Y. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18:128.CrossRef Kim YG, Han K, Choi J, Boo KY, Kim DY, Oh SK, Lee KN, Shim J, Kim JS, Kim Y. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18:128.CrossRef
17.
go back to reference Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25:853–8.CrossRef Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25:853–8.CrossRef
18.
go back to reference Steinhubl SR, Mehta RR, Ebner GS, Ballesteros MM, Waalen J, Steinberg G, Van Crocker P, Felicione E Jr, Carter CT, Edmonds S, et al. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening to Prevent Strokes (mSToPS) trial. Am Heart J. 2016;175:77–85.CrossRef Steinhubl SR, Mehta RR, Ebner GS, Ballesteros MM, Waalen J, Steinberg G, Van Crocker P, Felicione E Jr, Carter CT, Edmonds S, et al. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening to Prevent Strokes (mSToPS) trial. Am Heart J. 2016;175:77–85.CrossRef
19.
go back to reference Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, et al. Effect of a home-based wearable continuous ecg monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS Randomized Clinical Trial. JAMA. 2018;320(2):146–55.CrossRef Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, et al. Effect of a home-based wearable continuous ecg monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS Randomized Clinical Trial. JAMA. 2018;320(2):146–55.CrossRef
20.
go back to reference Hanchak NA, Murray JF, Hirsch A, McDermott PD, Schlackman N. USQA health profile database as a tool for health plan quality improvement. Manag Care. 1996;Q 4(2):58–69. Hanchak NA, Murray JF, Hirsch A, McDermott PD, Schlackman N. USQA health profile database as a tool for health plan quality improvement. Manag Care. 1996;Q 4(2):58–69.
21.
go back to reference Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):141–7.CrossRef Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):141–7.CrossRef
22.
go back to reference Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM. Atrial fibrillation in hemodialysis patients. Clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098–106.CrossRef Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM. Atrial fibrillation in hemodialysis patients. Clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098–106.CrossRef
23.
go back to reference Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA, Hou Q, Shireman TI. The prevalence of and factors associated with chronic atrial fibrillation in medicare/Medicaid eligible dialysis patients. Kidney Int. 2012;81:469–76.CrossRef Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA, Hou Q, Shireman TI. The prevalence of and factors associated with chronic atrial fibrillation in medicare/Medicaid eligible dialysis patients. Kidney Int. 2012;81:469–76.CrossRef
24.
go back to reference Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128(5):509–18.CrossRef Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128(5):509–18.CrossRef
25.
go back to reference Ahmadi SS, Svensson A, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19:9.CrossRef Ahmadi SS, Svensson A, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19:9.CrossRef
26.
go back to reference Liao J, Chao T, Liu C, Wang K, Chen S, Lin Y, Chang S, Lo L, Hu Y, Tuan T, Chung F, Chen T, Chen S. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209–15.CrossRef Liao J, Chao T, Liu C, Wang K, Chen S, Lin Y, Chang S, Lo L, Hu Y, Tuan T, Chung F, Chen T, Chen S. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209–15.CrossRef
27.
go back to reference Bansal N, Fan D, Hsu C, Ordonez J, Marcus G, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569–74.CrossRef Bansal N, Fan D, Hsu C, Ordonez J, Marcus G, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569–74.CrossRef
28.
go back to reference Tuan TC, Chang SL, Tsao HM, et al. The impact of age on the electroanatomical characteristics and outcome of catheter ablation inpatients with atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:966–72.CrossRef Tuan TC, Chang SL, Tsao HM, et al. The impact of age on the electroanatomical characteristics and outcome of catheter ablation inpatients with atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:966–72.CrossRef
29.
go back to reference Hsieh MH, Lin YJ, Wang HH, et al. Functional characterization of atrial electrograms in a pacing-induced heart failure model of atrial fibrillation: importance of regional atrial connexin40 remodeling. J Cardiovasc Electrophysiol. 2013;24:573–82.CrossRef Hsieh MH, Lin YJ, Wang HH, et al. Functional characterization of atrial electrograms in a pacing-induced heart failure model of atrial fibrillation: importance of regional atrial connexin40 remodeling. J Cardiovasc Electrophysiol. 2013;24:573–82.CrossRef
30.
go back to reference Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, Kuo CT, Yeh YH. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18:125.CrossRef Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, Kuo CT, Yeh YH. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18:125.CrossRef
31.
go back to reference Fontes JD, Lyass A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, Wang TJ, Vasan RS, Lubitz SA, Magnani JW, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109(1):87–90.CrossRef Fontes JD, Lyass A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, Wang TJ, Vasan RS, Lubitz SA, Magnani JW, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109(1):87–90.CrossRef
32.
go back to reference Cho ME, Craven TE, Cheung AK, Glasser SP, Rahman M, Soliman EZ, Stafford RS, Johnson KC, Bates JT, Burgner A, et al. The association between insulin resistance and atrial fibrillation: a cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). J Clin Hypertens (Greenwich). 2017;19(11):1152–61.CrossRef Cho ME, Craven TE, Cheung AK, Glasser SP, Rahman M, Soliman EZ, Stafford RS, Johnson KC, Bates JT, Burgner A, et al. The association between insulin resistance and atrial fibrillation: a cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). J Clin Hypertens (Greenwich). 2017;19(11):1152–61.CrossRef
33.
go back to reference Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565–71.CrossRef Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565–71.CrossRef
Metadata
Title
Chronic kidney disease and undiagnosed atrial fibrillation in individuals with diabetes
Authors
Nam Ju Heo
Sang Youl Rhee
Jill Waalen
Steven Steinhubl
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01128-y

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine